Towards a Treatment for RAS-MAPK Pathway Disorders
暂无分享,去创建一个
[1] Frank McCormick,et al. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. , 2007, Human molecular genetics.
[2] G. Daley,et al. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single‐agent therapy with imatinib , 2007, Cancer.
[3] Michael J Ackerman,et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy , 2007, Nature Genetics.
[4] G. Dorn,et al. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. , 2007, The Journal of clinical investigation.
[5] I. Pollack,et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] G. Mufti,et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome , 2007 .
[7] C. Der,et al. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.
[8] Y. Makita,et al. Leukemia in Cardio-facio-cutaneous (CFC) Syndrome: A Patient With a Germline Mutation in BRAF Proto-oncogene , 2007, Journal of pediatric hematology/oncology.
[9] R. A. Etten,et al. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.
[10] Vivienne Marsh,et al. Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.
[11] P. Greenberg,et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. , 2007, Blood.
[12] M. Patton,et al. The natural history of Noonan syndrome: a long-term follow-up study , 2006, Archives of Disease in Childhood.
[13] Wendy Schackwitz,et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome , 2006, Nature Genetics.
[14] Li Li,et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome , 2007, Nature Genetics.
[15] M. Bergo,et al. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. , 2006, The Journal of clinical investigation.
[16] B. Gelb,et al. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. , 2006, American journal of human genetics.
[17] Stephen G Young,et al. A Protein Farnesyltransferase Inhibitor Ameliorates Disease in a Mouse Model of Progeria , 2006, Science.
[18] D. Barford,et al. PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects* , 2006, Journal of Biological Chemistry.
[19] R. Hennekam,et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome , 2006, Nature Genetics.
[20] Kam Y. J. Zhang,et al. Germline KRAS mutations cause Noonan syndrome , 2006, Nature Genetics.
[21] R. Arceci,et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[23] G. Daley,et al. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy , 2006, Cancer.
[24] M. Vidaud,et al. Noonan syndrome: relationships between genotype, growth, and growth factors. , 2006, The Journal of clinical endocrinology and metabolism.
[25] M. Loh,et al. Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study. , 2005 .
[26] Alcino J. Silva,et al. The HMG-CoA Reductase Inhibitor Lovastatin Reverses the Learning and Attention Deficits in a Mouse Model of Neurofibromatosis Type 1 , 2005, Current Biology.
[27] Yukichi Tanaka,et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome , 2005, Nature Genetics.
[28] J. Schellens,et al. Development of farnesyl transferase inhibitors: a review. , 2005, The oncologist.
[29] Bruce D Gelb,et al. Noonan syndrome and related disorders: genetics and pathogenesis. , 2005, Annual review of genomics and human genetics.
[30] Edward S. Kim,et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane‐refractory/resistant nonsmall cell lung carcinoma , 2005, Cancer.
[31] P. LoRusso,et al. A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer , 2005 .
[32] Dirk Strumberg,et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] H. Varmus,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.
[34] J. Hecht,et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[36] D. Gilliland,et al. Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation , 2004, Nature Medicine.
[37] Edward S. Kim,et al. Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors , 2004, Clinical Cancer Research.
[38] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[39] Hiroyuki Tanaka,et al. Clinical evaluation of recombinant human growth hormone in Noonan syndrome. , 2004, Endocrine journal.
[40] M. Dowsett,et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] H. Ropers,et al. Spectrum of mutations in PTPN11 and genotype–phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome , 2003, European Journal of Human Genetics.
[42] E. Zackai,et al. Further delineation of cardiac abnormalities in Costello syndrome. , 2002, American journal of medical genetics.
[43] J. Fryns,et al. PTPN11 mutations in LEOPARD syndrome , 2002, Journal of medical genetics.
[44] M. Digilio,et al. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. , 2002, American journal of human genetics.
[45] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[46] E. Zackai,et al. Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. , 2002, American journal of medical genetics.
[47] Alcino J. Silva,et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1 , 2002, Nature.
[48] Michael A. Patton,et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.
[49] K. Gripp,et al. Second case of bladder carcinoma in a patient with Costello syndrome. , 2000, American journal of medical genetics.
[50] E. Mantadakis,et al. Prevalence of priapism in children and adolescents with sickle cell anemia. , 1999, Journal of pediatric hematology/oncology.
[51] S. Shoelson,et al. Crystal Structure of the Tyrosine Phosphatase SHP-2 , 1998, Cell.
[52] Paul W. Frankland,et al. A mouse model for the learning and memory deficits associated with neurofibromatosis type I , 1997, Nature Genetics.
[53] T. Katori,et al. Cardiovascular abnormalities in Noonan syndrome: The clinical findings and treatments , 1996, Acta paediatrica Japonica : Overseas edition.
[54] O Yoshida,et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. , 1995, Cancer research.
[55] M. Piombo,et al. Acute lymphoblastic leukemia in Noonan syndrome: report of two cases. , 1993, Medical and pediatric oncology.
[56] S. Sebti,et al. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. , 1991, Cancer communications.